BusinessImmuron Limited Issues Correction to Misleading Halt Announcement HeadlineBy Nasdaq OMXMar 7, 2018, 10:06 PM UTC
BusinessImmuron Enrols First Patients in Clinical Study of IMM-529 for Treatment of Clostridium Difficile Infection (CDI)By Nasdaq OMXJan 31, 2018, 2:30 PM UTC
BusinessUS Defense Reports Broad Travelan® Reactivity to 180 Pathogenic Bacteria Including Camylobacter and ShigellaBy Nasdaq OMXJan 29, 2018, 2:20 PM UTC
